52-week adjusted-price high
ActiveAdjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.
Free trial
Ask AI to review this stock
Copy the prompt to get recent events, historical reactions, and a short research brief.
Tell your AI:
Help me set up FinLab and analyze BEAM Beam Therapeutics Inc.. Please read: https://finlab.finance/en/setup?stock=BEAM
BEAM
Beam Therapeutics Inc. Healthcare As of 2026-07-08
quality needs a look, discounted valuation.
Is Beam Therapeutics Inc. a buy? Fundamentals and valuation first
-
Quality is weaker than peers. Operating margin is only around the 9th percentile. TTM ROE is about -5.6%.
-
Valuation is cheaper than most peers. TTM P/E is in the 6th percentile, lower than most liquid US common stocks.
-
Recent volatility is elevated. 60-day annualized volatility is in the 74th percentile. Average 20-day dollar volume is about $87.8M.
-
Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum, Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.
Historical evidence
Signals active now
Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.
Top-quintile 6-month momentum
Active · now 81.50388936905792%The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.
Average forward return after Top-quintile 6-month momentum。20-day: Win 36.8%, Sample 19, Median -11.33%, Excess -4.8%, Beat mkt rate 31.6%；60-day: Win 33.3%, Sample 18, Median -13.21%, Excess +14.92%, Beat mkt rate 27.8%；120-day: Win 35.3%, Sample 17, Median -23.85%, Excess +16.83%, Beat mkt rate 29.4%
120 days after: historical avg +24.1%
20-day -3.41%
60-day +18.81%
120-day +24.1%
20-day
60-day
120-day
Win
36.8%
33.3%
35.3%
Sample
19
18
17
Median
-11.33%
-13.21%
-23.85%
Excess
-4.8%
+14.92%
+16.83%
Beat mkt rate
31.6%
27.8%
29.4%
Over 17 occurrences, 120-day forward avg gained 24.1%, beat the market by 16.83 pts; win rate 35.3%.
Filed revenue acceleration
Active · now 157.96816508855264%TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.
Average forward return after Filed revenue acceleration。20-day: Win 12.5%, Sample 8, Median -14.52%, Excess -13.81%, Beat mkt rate 12.5%；60-day: Win 14.3%, Sample 7, Median -28.76%, Excess -18.63%, Beat mkt rate 14.3%；120-day: Win 16.7%, Sample 6, Median -36.51%, Excess -25.36%, Beat mkt rate 16.7%
120 days after: historical avg -26.45%
20-day -12.92%
60-day -18.32%
120-day -26.45%
20-day
60-day
120-day
Win
12.5%
14.3%
16.7%
Sample
8
7
6
Median
-14.52%
-28.76%
-36.51%
Excess
-13.81%
-18.63%
-25.36%
Beat mkt rate
12.5%
14.3%
16.7%
Over 6 occurrences, 120-day forward avg declined 26.45%, lagged the market by 25.36 pts; win rate 16.7%.
Market-wide momentum baseline
Across 94,467 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.44%, a 58.2% positive-return rate, and +3.09 percentage points of average excess return versus the S&P 500.
Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).
Signals not active now
Inactive signals still show the stock-specific historical forward-return distribution for context.
EPS surprise beat
PendingReported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.
12 times historically; 60-day forward avg -12.29%, win rate 27.3%, beating the market by -12.74 pts on average.
Method and limits
- Returns use us_price:adj_close, adjusted for splits and dividends where available.
- Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
- Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
- The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
- Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
- Overlapping event windows are descriptive distributions, not independent samples.
This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.